Streetwise Expert Interviews

Three Biotechs that Could Radically Change the Practice of Medicine Forever: Wasatch Analyst Jill Wahleithner

Buyside analysts don't publish ratings and target prices for the public: Nearly all their notes, analyses and projections are top secret. However, in this interview with The Life Sciences Report, Wasatch Advisors' Jill Wahleithner breaks that tacit rule. Wahleithner, a former big pharma scientist, identifies three unusual biotechs with advanced therapeutic technology platforms that could turn the tide against conditions that have plagued humankind for eons, and the potential returns on investment matches the potential to completely and radically change the practice of medicine forever.

(3/25/15) More >
Read More Streetwise Interviews

How ARM's Edward Lanphier Is Fighting for Cell Therapy Cures that Save Patients and Portfolios

Edward Lanphier, current chairman of the Alliance for Regenerative Medicine, sees near-term milestones for stem cell, gene therapy and genetically modified cell therapy companies on the horizon, as well as additional inflows of validating capital from prominent investors. (3/19/15) More >

Will Stem Cell Profits Measure Up?: NxR Biotechnologies' Alain Vertès

Cell therapies may ultimately be more useful and more curative than drugs, and hence more valuable. That's the way Alain Vertès of NxR Biotechnologies sees it, and he names companies in the field that investors can bank on. (3/17/15) More >

Newsletter Briefs

"INO's idea of using DNA, which is simple to make and cost-effective, to drive the body's natural immune response is just fascinating." (3/25/15) Inovio Pharmaceuticals Inc. - The Life Sciences Report Interview with Jill Wahleithner More >

"ATHX's Multistem could very well be among the first few products approved in Japan." (3/17/15) Athersys Inc. - The Life Sciences Report Interview with Alain Vertès More >

"Right now, RP is positioned with very good potential." (3/17/15) RepliCel Life Sciences Inc. - The Life Sciences Report Interview with Alain Vertès More >

"MSB's technology is rock solid." (3/17/15) Mesoblast Ltd. - The Life Sciences Report Interview with Alain Vertès More >

"CTRV's experienced management team knows how to present well, and investors are responding." (3/4/15) ContraVir Pharmaceuticals Inc. - The Life Sciences Report Interview with Alan Leong More >

"RP is going for a best-of-breed solution." (3/4/15) RepliCel Life Sciences Inc. - The Life Sciences Report Interview with Alan Leong More >

"Investors should keep a close eye on CBMG during 2015." (2/19/15) Cellular Biomedicine Group Inc. - The Life Sciences Report Interview with Stephen Dunn More >

"CANF's oral psoriasis candidate has shown some very, very promising data." (1/27/15) Can-Fite BioPharma Ltd. - The Life Sciences Report Interview with Reni Benjamin More >

Expert Analysis

"There is substantial upside to revenue and EBITDA forecasts for NHC." (3/24/15) Nobilis Health Corp. - Russell Stanley, Mackie Research Capital More >

"CANF's agreement with Cipher validates the commitment to CF101." (3/23/15) Can-Fite BioPharma Ltd. - Joseph Pantginis, ROTH Capital Partners More >

"NHC's Q4/14 revenue increased 193%; its FY14 revenue increased 170%." (3/23/15) Nobilis Health Corp. - Sheila Broughton, PI Financial More >

"The next event for CPXX's CPX-351 is induction response data in Q2/15." (3/20/15) Celator Pharmaceuticals Inc. - Andrew Fein, H.C. Wainwright & Co. More >

"MSB was selected by JETRO for access to potential investment." (3/19/15) Mesoblast Ltd. - Henry McCusker, Regenerative Medicine Investors More >

"CTH will conduct a short bridging study, CTH-200, to start in Q2/15." (3/18/15) Cynapsus Therapeutics Inc. - Jason Napodano, Zacks Small-Cap Research More >

"CUR's Phase 2 ALS study showed a 47% rate of response to NSI-566." (3/18/15) Neuralstem Inc. - John Peabody, Seeking Alpha More >

"We initiate coverage on RNN with a Buy rating." (3/20/15) Rexahn Pharmaceuticals Inc. - Vernon Bernardino, MLV & Co More >